Skip to content
AnalystLens

IDEXX Laboratories Annual Report, Year Ended Dec 31, 2014

Filing Date
Filed February 17, 2015
Period End
December 31, 2014
Security
IDXX
One revenue dollarkept$0.12
In the record · 2016–202610-K1110-Q338-K98

IDXX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 98 current reports (8-K) between 2016 and 2026.

  1. FY2016 annual report10-K · Feb ’17Feb ’17
  2. Leadership change8-K · Oct ’19Oct ’19
  3. Material agreement8-K · Dec ’21Dec ’21
  4. Leadership change8-K · Jan ’26Jan ’26

Summary

Summary of the 10-K filed February 17, 2015. Cited figures are marked; the original filing is the authoritative source.

IDEXX Laboratories' FY2014 10-K shows a company growing revenue 7.9% to $1.486 billiona (organic growth of 8.0%) while absorbing a deliberate one-time transition to an all-direct U.S. sales model effective January 1, 2015.

Companion Animal Group (CAG) generated 83% of revenue and is driven by recurring diagnostics (about 71% of consolidated revenue), including VetLab consumables, reference lab services and rapid assays. Operating income fell 2.4% to $260.3 millionb, and operating margin declined to 17.5% from 19.4%, largely because of about $35.3 million in transition impacts (distributor inventory drawdown, ramp-up costs and non-recurring expenses). Management's adjusted operating income was about $295.6 million (19.6% of revenue), up 9.1%.

Diluted EPS rose to $3.58c from $3.48, helped by a 7% reduction in diluted share count to 50.8 million shares. The company repurchased $618 million of stock (4.9 million shares) and increased debt, with total long-term debt of $350 million plus a $549 million revolving credit line classified as current. Stockholders' equity fell to $117.6 million from $518.2 million, and working capital turned negative at $(61.5) million.

Management expects the all-direct transition to add $50d–55 million in annual revenue and $5–8 million in 2015 operating profit, with $15–20 million in extra working capital needs. Key risks include sole-source supplier dependence (such as Ortho chemistry slides), loss of distributor relationships, competition from Antech/VCA, Abaxis, Heska and Zoetis, the strong U.S. dollar (about 28% of revenue is U.S.-manufactured and sold internationally), corporate hospital consolidation, and the approaching expiration of the SNAP immunoassay patents in 2015. The PwC audit opinion was unqualified and internal controls were rated effective.

Key Highlights

  1. Revenue rose 7.9% to $1,485.8 million (organic growth 8.0%), with CAG Diagnostics recurring revenue up 8.2% to $1,053.4 million, about 71% of total revenue.
  2. Operating income declined 2.4% to $260.3 million (operating margin 17.5% vs. 19.4%), reflecting roughly $35.3 million in one-time costs from the U.S. all-direct sales transition; adjusted operating income was about $295.6 million (19.6% margin).
  3. Diluted EPS increased to $3.58 from $3.48, supported by share repurchases of $618.2 million (4.9 million shares) that cut diluted weighted shares by about 6%.
  4. Net income attributable to IDEXX fell slightly to $181.9 million from $187.8 million, with higher interest expense of $15.4 million (vs. $5.4 million) from $350 million of new senior notes.
  5. Stockholders' equity dropped to $117.6 million from $518.2 million and working capital turned negative at $(61.5) million, driven by the buybacks and a $549 million revolver classified as current.
  6. Management expects the all-direct U.S. model to add $50–55 million in annual revenue and $5–8 million in 2015 operating profit, while requiring $15–20 million in additional working capital.
  7. International sales were about 43% of revenue, with strong growth in Europe and Asia-Pacific; the company has no plans to pay dividends.

Follow one dollar

Of each $1.00 of revenue in FY2014, IDEXX Laboratories kept $0.12.

  1. Revenue$1.49B100.0%
  2. Cost of revenue−$669.7M45.1%
  3. Gross profit$816.1M54.9%
  4. Operating costs−$555.9M37.4%
  5. Operating income$260.3M17.5%
  6. Interest, other & tax−$78.3M5.3%
  7. Net income$181.9M12.2%
Computed from 10-KFY2014filed February 17, 2015Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Where FY2014 revenue went

$1.49B
  • Cost of revenue: $669.7M, 45% of revenue
  • Other operating costs: $457.6M, 31% of revenue
  • Net income: $181.9M, 12% of revenue
  • R&D: $98.3M, 6.6% of revenue
  • Interest, other & tax: $78.3M, 5.3% of revenue

Kept 12% as net income

Full revenue history →

Financial Statements

FY2014 against FY2013

Line itemFY2014FY2013Change
Revenue$1.49B$1.38B+7.9%
Cost of Revenue$669.69M$620.94M+7.9%
Gross Profit$816.12M$756.12M+7.9%
R&D Expenses$98.26M$88.00M+11.7%
Operating Income$260.25M$266.76M−2.4%
Interest Expense$15.43M$5.39M+186.5%
Net Income$181.91M$187.80M−3.1%
EPS (Basic)$1.82$1.77+2.8%
EPS (Diluted)$1.79$1.74+2.9%
Shares Outstanding (Basic)100.09M106.32M−5.9%
Shares Outstanding (Diluted)101.50M107.97M−6.0%

Frequently Asked Questions

  1. Why did operating margin decline in 2014 even though revenue grew nearly 8%?

    Operating margin fell from 19.4% to 17.5% mainly because of costs tied to the transition to an all-direct sales model in the U.S. These included about $20.8 million from the drawdown of distributor inventory, $5.0 million in ramp-up expenses and $9.5 million in non-recurring costs. Excluding these items, adjusted operating income was about $295.6 million, or 19.6% of revenue. Higher sales and marketing spending and currency losses in unallocated amounts also contributed.

  2. What is the all-direct sales strategy and what does it mean for future revenue?

    Effective January 1, 2015, IDEXX stopped renewing its U.S. distributor agreements and now sells rapid assay kits and instrument consumables directly to veterinary practices, consistent with its direct model for instruments and reference labs. Management expects an extra $50–55 million in annual revenue and $5–8 million in annual operating profit in 2015, with benefits scaling over time. The change also brings $15–20 million in added working capital needs, and the company faces risk that former distributors, two of which now carry competing products, may affect customer retention.

  3. How is IDEXX's balance sheet and capital structure changing?

    Total assets grew to $1.38 billion, but equity fell to $117.6 million because of $618 million in share repurchases. Long-term debt rose to $350 million from $150 million through senior notes issued in 2013–2014, and a $549 million revolving credit facility, which matures in 2019 but is classified as current because of its short borrowing terms, pushed working capital negative. The company also issued $150 million of additional senior notes in February 2015. Covenants require a leverage ratio of 3.5x or less, and management says it was in compliance at year end.

  4. What are the biggest risks to IDEXX's business according to the filing?

    Key risks include reliance on sole- and single-source suppliers, such as Ortho for VetTest and Catalyst chemistry slides under agreements through 2028; competition from Antech Diagnostics, Abaxis, Heska and Zoetis; consolidation of corporate veterinary hospitals and buying groups; the strong U.S. dollar, which affects about 28% of revenue; and the expiration of SNAP immunoassay patents in 2015. Regulatory approvals from the USDA, FDA and EPA, along with biologic manufacturing complexity and cybersecurity, add further risk.